Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy
Although retrospective, the marked OS difference between aXRT and dXRT groups suggests that aXRT may be not be as beneficial as what was once thought, especially regarding long-term survival. These results also offer justification for the use of a dXRT group in studies assessing adjuvant treatments, as well as a reconsideration of the current treatment paradigm for these patients, especially given the recent introduction of IDH inhibitors.
Authors
- Tresa McGranahan (ORCID: https://orcid.org/0000-0003-0472-4252)
- Seema Nagpal (ORCID: https://orcid.org/0000-0002-0289-2319)
- Lawrence David Recht (ORCID: https://orcid.org/0000-0001-8614-2189)
- Isabella Densmore (ORCID: https://orcid.org/0000-0003-4607-3603)
- Tyler Lanman (ORCID: https://orcid.org/0000-0001-8746-282X)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
- Center for Neuro-Oncology (US)
- Dana-Farber Cancer Institute (US)
- Scripps MD Anderson Cancer Center (US)
- Harbor–UCLA Medical Center (US)
- Stanford University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1212/wnl.0000000000213797
- Citations
- 4
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.50